NEW YORK, Feb 9, 2026, 09:07 EST — Premarket
- Kenvue shares edged about 0.4% higher in premarket action, sitting near $18.
- The stock remains under the implied value of Kimberly-Clark’s cash-and-stock bid.
- This week, investors are watching the Feb. 11 dividend record date. Results land after the close on Feb. 17.
Kenvue Inc picked up roughly 0.4% before the bell Monday, trading at $18.13. Investors tracked the stock with the company’s pending sale in the background and a packed slate of U.S. economic releases ahead.
Not much movement across the broader market. Wall Street futures barely budged in early trading, coming off a sharp rally late last week that snapped a rough spell for big tech stocks. Investors are still trying to gauge just how much the AI wave will demand in terms of spending.
Kenvue’s short-term picture hinges on the deal. Kimberly-Clark sits near $104.33, and based on the offer, that spits out about $19.15 per Kenvue share. Early action has Kenvue trailing the implied price by about a buck.
Merger-arb traders make their bets on that gap: the difference between the offer’s value and Kenvue’s price. Whenever investors factor in legal risk, possible delays, or a turn in the market, that spread can blow out fast.
On Jan. 29, both Kimberly-Clark and Kenvue reported that shareholders gave a resounding yes to the deal. Kenvue CEO Kirk Perry described it as “strong support,” with both groups of investors clearing a path for the companies to move ahead and finish the transaction before year-end. Kenvue
The deal still needs to clear several hurdles. According to a regulatory filing, U.S. antitrust approval is required along with other sign-offs, and an “outside date” has been set for Nov. 2, 2026. That deadline could be pushed back if regulators take longer to review.
Kenvue will post its fourth-quarter and full-year 2025 numbers after the bell on Feb. 17, but there won’t be a conference call this time. The company cited the pending deal as the reason.
Dividends getting attention again: Kenvue’s board declared a quarterly payout of $0.2075 a share, with the check set to go out Feb. 25. The cutoff to qualify is Feb. 11—investors need to be listed as shareholders by then.
Still, the trade comes with its share of risk. The company is dealing with lawsuits over Tylenol and other products, while Texas has tried to stop a Kenvue dividend before, suing over what it called deceptive acetaminophen marketing. That history clouds both the timing and investor sentiment around any potential takeover.
Kenvue’s stock often moves in step with the broader market—think shifts in rates or sentiment toward consumer staples. Still, deal mechanics usually call the shots: what’s happening with the acquirer’s share price, the ticking clock, or any sign of trouble in the approval process.
